Full-Time
Posted on 9/9/2025
Guides clinical development and commercialization
No salary listed
Dublin, Ireland
Hybrid
Hybrid: 2 days per week in office at Citywest Business Campus, Ireland.
Inizio helps health and life sciences companies develop and commercialize products to maximize patient access. It uses a connected suite of capabilities and expert guidance to navigate assets through their entire lifecycle with tailored strategies. Unlike firms that offer single services, Inizio combines multiple capabilities in an end-to-end approach focused on reducing complexity and ensuring lifecycle support. Its goal is to bring therapies to patients faster and more effectively by coordinating development, regulatory, market access, and commercialization activities to maximize value and treatment outcomes.
Company Size
5,001-10,000
Company Stage
N/A
Total Funding
N/A
Headquarters
New York City, New York
Founded
N/A
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
Performance Bonus
Professional Development Budget
Hybrid Work Options
LONDON, Feb. 6, 2025 /PRNewswire/ -- Inizio, a commercialization partner for health and life science companies, has today announced the appointment of Colin Stanley as Chief Commercial Officer (CCO), Remco op den Kelder as President of Inizio Advisory and Jim Sage as President of Inizio Engage.Stepping into the CCO role, Colin brings over 25 years of sector experience and a proven track record in business growth in the industry, from CRO and commercialization
Inizio Medical, the leading provider of Medical Affairs and communications solutions, today announced the appointment of Patrick Giordani as Senior Vice President, AI Solutions Architect.
Bio-IT World Inc is immensely proud that Matt has chosen to join Inizio Medical and contribute to its mission of providing exceptional medical communications and specialized solutions.
FORT WASHINGTON, Pa., Oct. 18, 2023 /PRNewswire/ -- Inizio Engage has announced the launch of Nazaré, a new learning and capability brand. Nazaré brings together 150+ experts in learning, life sciences, creativity, technology, and behavioral science. Nazaré is set to transform workplace learning in order to help companies maintain their leadership in evolving competitive landscapes by unlocking the potential of their people.The new global learning and capability brand will be part of the Experience Design (XD) specialist area within Inizio Engage. This means Nazaré will draw on the rest of Inizio Engage XD's in-house creative and executional capabilities in live events, environments, film, digital, and immersive technologies, as well as considering learning experience design more holistically alongside employee engagement.Nazaré brings together Axiom, Cormis, Logicearth Learning Services and Ashfield Excellence Academy under one brand to support global organizations with a range of learning and capability programs, with an unparalleled level of expertise in end-to-end life sciences learning support for pharmaceutical and biotech companies across the product lifecycle. Nazaré will focus on designing and delivering world-class learning experiences that inspire an immediate and lasting change in performance.Nazaré harnesses science, creativity, and technology to challenge how the Learning & Development industry creates impact for businesses
SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials in Japan. The former specialises in clinical trial site recruitment and retention and project management solutions, while the latter operates a cutting-edge real-time health insights exchange platform.Mr Taketeru Inokawa (left) and Dr Huren Sivaraj (right) during the MOU signing ceremony in Singapore.The collaboration will extend to Oncoshot's strategic contract research organisation and pharmaceutical partners. Together, they will focus on recruiting participants for upcoming studies scheduled to begin in Q1 2024."This collaboration marks a significant step in Oncoshot's vision of creating a cancer cohort discovery platform and upcoming national-level clinical trials ecosystems and hospitals globally," said Oncoshot CEO Dr Huren Sivaraj.Central to this partnership is the cost-free infrastructure designed to facilitate the real-time exchange of aggregated insights. This ground-breaking initiative is set to synergise their complementary strengths to enhance various clinical trial aspects throughout Japan, including feasibility assessments, participant screening, and enrolment. Japan is currently ranked as the third-largest pharmaceutical market worldwide